The Next
Generation
Triple Agonist
NZReta is New Zealand’s retatrutide research hub. Retatrutide simultaneously activates three metabolic receptors — GIP, GLP-1, and glucagon. In our full Reta NZ guide, we explain what Reta is, how the triple agonist works, what current Phase 3 results show, and how it compares with existing GLP-1 medicines.
TRIUMPH-1: 28.3% Mean Weight Loss at 80 Weeks
What Lilly’s broader Phase 3 obesity readout reported, how the 104-week extension differs, and the limits of company-reported topline data.
Triple Receptor Agonism: Why the GCGR Target Changes Everything
How glucagon receptor activation sets retatrutide apart from existing GLP-1 therapies.
Retatrutide in New Zealand: Current Medsafe Context
What investigational status means, how Medsafe treats unapproved peptide products, and why online availability is not approval.
Retatrutide NZ status, trial data and Medsafe context.
Retatrutide remains investigational and is not an approved consumer medicine in New Zealand. NZReta maintains a 2026 status guide covering Medsafe context, clinical trial updates, fake-product risks and COA verification issues for New Zealand readers.
Three Targets.
One Molecule.
Where semaglutide and tirzepatide act on one or two receptors, Reta (retatrutide) (LY3437943) is a once-weekly injectable peptide that simultaneously activates the GIP, GLP-1, and glucagon receptors — the first of its kind to reach late-stage clinical development.
The additional glucagon receptor component may drive significantly greater energy expenditure and fat oxidation compared to GLP-1 monotherapy, which researchers believe may explain the higher weight-loss figures seen in trials.
For a deeper comparison, see our retatrutide vs semaglutide comparison and our retatrutide vs tirzepatide analysis.
- GLPreceptorGLP-1 Receptor AgonismReduces appetite and food intake. Slows gastric emptying. Shared mechanism with semaglutide and tirzepatide. Learn more in our GLP-1 mechanism guide.
- GIPreceptorGIP Receptor AgonismEnhances insulin secretion and may influence GLP-1 receptor sensitivity. Also active in tirzepatide.
- GCGreceptorGlucagon Receptor AgonismThe third target — associated with increased energy expenditure, hepatic fat changes, and retatrutide’s distinct research profile.
Latest Research
& Analysis
All GuidesReta NZ: Complete Research Guide
A complete guide to what Reta means, how retatrutide works, current trial evidence, safety and New Zealand context.
Retatrutide vs Tirzepatide: Triple vs Dual Agonist
A direct comparison of retatrutide and tirzepatide, including receptor targets, weight-loss trial context, and mechanism differences.
Retatrutide vs Semaglutide: Next-Gen GLP-1 Research
How retatrutide compares with semaglutide across receptor activity, research outcomes, and clinical development.
The numbers
behind the first Phase 3 readout
This section summarises TRIUMPH-4 topline Phase 3 context. The broader TRIUMPH-1 obesity result is highlighted above. This site presents research information only. Individual outcomes vary. Not medical advice.
Primary sources: Lilly TRIUMPH-1 announcement · Lilly TRIUMPH-4 announcement · Medsafe peptide advisory
Retatrutide research, comparisons, and GLP-1 science.
Start with the complete Reta NZ guide, then explore how retatrutide compares with established metabolic research compounds including semaglutide and tirzepatide.
For a deeper mechanism breakdown, read our GLP-1 mechanism of action guide. You can also browse the full retatrutide guides library. For the latest regulatory and safety context, see our 2026 NZ status guide. For availability questions, see our where to buy retatrutide NZ guide, which covers availability, Medsafe context, COA checks and verification red flags.
Reta NZ Guide
The plain-language NZReta guide to what Reta is, how it works, trial evidence and safety context.
Read guide →Retatrutide vs Semaglutide
Compare triple agonist retatrutide with GLP-1 semaglutide across mechanism and research data.
Compare →Retatrutide vs Tirzepatide
Triple agonist vs dual agonist: a direct comparison for metabolic research context.
Compare →GLP-1 Mechanism of Action
Understand GLP-1, GIP, and glucagon receptor activity behind next-generation metabolic research.
Learn mechanism →All Retatrutide Guides
Browse the full NZReta research library and all published retatrutide-related guides.
View all guides →Retatrutide NZ 2026 Status Guide
Current NZ status, Medsafe context, trial data, fake-product risks and COA verification issues in one trust-focused guide.
Read status guide →Can You Buy Retatrutide in NZ?
A careful availability guide covering legal status, Medsafe context, COA verification, and red flags for New Zealand readers.
View availability guide →Is My Retatrutide Fake?
Learn how to identify fake, underdosed, or unverified retatrutide using COAs, mass spec, batch matching, and supplier transparency checks.
Read guide →Retatrutide Clinical Trials NZ
A full breakdown of retatrutide clinical trial data including Phase 2 studies, TRIUMPH, TRANSCEND, obesity outcomes, and future development.
View trials →